Table 1.

Demographic characteristics and hormone levels of subjects (cases and subcohort)

Prostate cancer cases
Subcohort (n = 1,826)
Aggressive* (n = 88)Nonaggressive (n = 430)
Age at baseline (y), n (%)
    <502 (2)18 (4)578 (32)
    50-5914 (16)120 (28)565 (31)
    60+72 (82)292 (68)683 (37)
Country of birth, n (%)
    Australia/New Zealand/United Kingdom72 (82)342 (80)1,321 (72)
    Italy13 (15)49 (11)260 (14)
    Greece3 (3)39 (9)245 (13)
Smoking, n (%)
    Never33 (38)176 (41)723 (40)
    Former49 (56)209 (49)815 (45)
    Current6 (7)45 (11)288 (16)
Alcohol (g/d), n (%)
    No alcohol25 (28)88 (21)337 (18)
    1-3949 (56)275 (64)1,172 (64)
    40+14 (16)66 (15)315 (17)
Body mass index, mean (SD)27.9 (3.8)27.1 (3.5)27.2 (3.6)
Hormone and PSA levels, median (interquartile range)
    PSA (ng/mL)4.6 (2.1-18.4)3.4 (1.9-6.9)0.8 (0.5-1.5)
    IGF-I (nmol/L)22 (19-26)22 (17-28)23 (18-29)
    IGFBP-3 (nmol/L)107 (93-123)106 (90-125)107 (91-124)
    IGF-I/IGFBP-3 molar ratio0.21 (0.19-0.25)0.21 (0.17-0.25)0.22 (0.18-0.26)
  • * A tumor was classified as aggressive if Gleason score was >7 or stage was advanced (T4 or N+ or M+). We were not able to define aggressiveness for six cases because Gleason score and tumor stage were not available (clinical diagnoses only).

  • The number of missing measures was 25 for PSA.

  • PSA levels at blood draw (baseline), not at diagnosis.